Concert Pharmaceuticals Inc. (CNCE)

6.20
0.11 1.80
NASDAQ : Health Technology
Prev Close 6.09
Open 6.12
Day Low/High 5.99 / 6.23
52 Wk Low/High 5.36 / 17.83
Volume 105.52K
Avg Volume 222.00K
Exchange NASDAQ
Shares Outstanding 23.80M
Market Cap 155.18M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Concert Pharmaceuticals Presents CTP-656 Phase 1 Results At European Cystic Fibrosis Conference

Concert Pharmaceuticals Presents CTP-656 Phase 1 Results At European Cystic Fibrosis Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented results from a Phase 1 multiple ascending dose trial of CTP-656, a next generation CFTR potentiator being developed for the treatment of cystic fibrosis.

Concert Pharmaceuticals Initiates Phase 1 Trial Of CTP-543 As A New Treatment For Alopecia Areata

Concert Pharmaceuticals Initiates Phase 1 Trial Of CTP-543 As A New Treatment For Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated its Phase 1 clinical program for CTP-543, which is being developed for the treatment of alopecia areata, an autoimmune disease for...

Concert Pharmaceuticals To Present At Several Upcoming Investor Conferences

Concert Pharmaceuticals To Present At Several Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The UBS 2016 Global Healthcare Conference on May...

Concert Pharmaceuticals Becomes Oversold (CNCE)

Concert Pharmaceuticals Becomes Oversold (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals Reports First Quarter 2016 Financial Results

Concert Pharmaceuticals Reports First Quarter 2016 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2016.

Concert Pharmaceuticals Unveils CTP-543 For Treatment Of Alopecia Areata

Concert Pharmaceuticals Unveils CTP-543 For Treatment Of Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced its next product candidate, CTP-543, for the treatment of alopecia areata.

Commit To Purchase Concert Pharmaceuticals At $12.50, Earn 26.7% Annualized Using Options

Commit To Purchase Concert Pharmaceuticals At $12.50, Earn 26.7% Annualized Using Options

Investors considering a purchase of Concert Pharmaceuticals Inc stock, but tentative about paying the going market price of $13.96/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $12.50 strike, which has a bid at the time of this writing of $1.60.

Concert Pharmaceuticals Announces Positive Data From Multiple Dose Phase 1 Clinical Trial Of CTP-656, Lead Candidate For The Treatment Of Cystic Fibrosis

Concert Pharmaceuticals Announces Positive Data From Multiple Dose Phase 1 Clinical Trial Of CTP-656, Lead Candidate For The Treatment Of Cystic Fibrosis

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced positive topline data from a Phase 1 multiple ascending dose clinical trial of CTP-656.

Concert Pharmaceuticals To Report First Quarter 2016 Financial Results On May 5, 2016

Concert Pharmaceuticals To Report First Quarter 2016 Financial Results On May 5, 2016

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2016 financial results on Thursday, May 5, 2016, before the U.

7 Stocks Rising on Big Volume -- Here's How to Trade Them Now

7 Stocks Rising on Big Volume -- Here's How to Trade Them Now

Here's a technical look at how to trade seven stocks that were spiking on unusual volume recently.

Concert Pharmaceuticals Names Christine Van Heek To Board Of Directors

Concert Pharmaceuticals Names Christine Van Heek To Board Of Directors

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Christine van Heek has been appointed to its Board of Directors and will serve as a member of its audit committee effective April 8, 2016.

5 Stocks Poised for Big Breakouts

5 Stocks Poised for Big Breakouts

These stocks look ready to break out and trade much higher from current levels.

Concert Pharmaceuticals Names Meghan FitzGerald To Its Board Of Directors

Concert Pharmaceuticals Names Meghan FitzGerald To Its Board Of Directors

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Meghan FitzGerald has been appointed to its Board of Directors and will serve as a member of its compensation committee effective March 22, 2016.

Concert Pharmaceuticals Reports Fourth Quarter And Year Ended 2015 Financial Results

Concert Pharmaceuticals Reports Fourth Quarter And Year Ended 2015 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the fourth quarter and year ended December 31, 2015 and provided an update on its product pipeline and corporate activities.

Concert Pharmaceuticals Announces CTP-656 Solid Dose Phase 1 Results Confirmed Superior Pharmacokinetic Profile To Kalydeco®

Concert Pharmaceuticals Announces CTP-656 Solid Dose Phase 1 Results Confirmed Superior Pharmacokinetic Profile To Kalydeco®

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced new results from Part 1 of its multiple ascending dose Phase 1 clinical trial in which a single-dose tablet formulation of CTP-656 was compared to the...

Concert Pharmaceuticals To Present At Several Upcoming Investor Conferences

Concert Pharmaceuticals To Present At Several Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The 36 th Annual Cowen and Company Healthcare...

Concert Pharmaceuticals To Report Full Year 2015 Results On March 1, 2016

Concert Pharmaceuticals To Report Full Year 2015 Results On March 1, 2016

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2015, on Tuesday, March 1, 2016, before the U.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABC, MFNC, POST, UTEK Downgrades: CBL, CNCE, DFT, ENLK, ETH, HTH, IXYS, KE, MFRM, NFG, PMT, PNNT, POWI, RENN, RSTI, SHO, SU, TDC, TPX, VLP, ZIXI Initiations: FFWM Read on to get TheStreet Quant Ratings' detailed report:

Concert Pharmaceuticals is Now Oversold (CNCE)

Concert Pharmaceuticals is Now Oversold (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Buy Concert Pharmaceuticals At $12.50, Earn 20.5% Annualized Using Options

Commit To Buy Concert Pharmaceuticals At $12.50, Earn 20.5% Annualized Using Options

Investors eyeing a purchase of Concert Pharmaceuticals Inc shares, but tentative about paying the going market price of $15.90/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $12.50 strike, which has a bid at the time of this writing of $1.20.

Oversold Conditions For Concert Pharmaceuticals (CNCE)

Oversold Conditions For Concert Pharmaceuticals (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Purchase Concert Pharmaceuticals At $17.50, Earn 22.6% Annualized Using Options

Commit To Purchase Concert Pharmaceuticals At $17.50, Earn 22.6% Annualized Using Options

Investors considering a purchase of Concert Pharmaceuticals Inc stock, but cautious about paying the going market price of $20.54/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July 2016 put at the $17.50 strike, which has a bid at the time of this writing of $2.35.

Concert Pharmaceuticals Achieves $2 Million Milestone From Avanir Pharmaceuticals For Phase 3 Initiation Of AVP-786 For Agitation In Patients With Alzheimer's Disease

Concert Pharmaceuticals Achieves $2 Million Milestone From Avanir Pharmaceuticals For Phase 3 Initiation Of AVP-786 For Agitation In Patients With Alzheimer's Disease

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals, Inc.

Concert Pharmaceuticals Initiates Phase 1 Multiple Ascending Dose Trial With CTP-656 For Cystic Fibrosis

Concert Pharmaceuticals Initiates Phase 1 Multiple Ascending Dose Trial With CTP-656 For Cystic Fibrosis

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a Phase 1 multiple ascending dose clinical trial with CTP-656.

Concert Pharmaceuticals (CNCE) Strong On High Relative Volume Today

Concert Pharmaceuticals (CNCE) Strong On High Relative Volume Today

Trade-Ideas LLC identified Concert Pharmaceuticals (CNCE) as a strong on high relative volume candidate

Concert Pharmaceuticals To Present At Upcoming Investor And Industry Conferences

Concert Pharmaceuticals To Present At Upcoming Investor And Industry Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: Jefferies Autumn 2015 Global Healthcare...

Concert Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Company Update

Concert Pharmaceuticals Reports Third Quarter 2015 Financial Results And Provides Company Update

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2015.

Concert Pharmaceuticals To Report Third Quarter 2015 Financial Results On November 5, 2015

Concert Pharmaceuticals To Report Third Quarter 2015 Financial Results On November 5, 2015

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2015 financial results on Thursday, November 5, 2015, before the U.

Concert Pharmaceuticals Highlights CTP-656 Phase 1 Results At North American Cystic Fibrosis Conference

Concert Pharmaceuticals Highlights CTP-656 Phase 1 Results At North American Cystic Fibrosis Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented results from a Phase 1 single ascending dose trial of CTP-656, a next generation potentiator being developed for the treatment of cystic fibrosis.

Concert Pharmaceuticals Announces $8 Million Milestone From Celgene

Concert Pharmaceuticals Announces $8 Million Milestone From Celgene

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has achieved an $8 million milestone under its development and license agreement with Celgene Corporation (NASDAQ: CELG) for completion of the Phase 1...

TheStreet Quant Rating: D (Sell)